Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
SKAN: CFO and division head to face Federal Criminal Court over suspicion of insider trading
Two senior employees of SKAN must answer to the Federal Criminal Court on suspicion of insider trading. The trial begins on 5 November, and the first-instance verdict is to be announced on 17 November. The CFO is alleged to have bought shares before the IPO and to have gained an alleged benefit of around 287,000 francs; the division head is accused of obtaining a benefit of about 5,600 francs. The board emphasizes the presumption of innocence and expresses its confidence in the managers; both remain in their positions. Proceedings against former board chairman Gert Thoenen were discontinued. » More on finanzen.net
SKAN reports strong half-year results and returns to profit
SKAN increased net revenues in 1H 2026 by 22.2% to CHF 164.5m (currency-adjusted +24.0%) and swung from a net loss of CHF 8.3m to a net profit of CHF 5.4m (EPS CHF 0.21). EBITDA rose to CHF 15.3m, operating cash flow to CHF 16.3m; order intake grew 16.3% to CHF 247.6m, and the order backlog increased 27.8% to CHF 442.3m. The Services & Consumables segment recorded an order intake increase of over 54%, and acquisitions contributed to results for the first time on a full-year basis. Management confirmed the annual guidance, expecting net sales growth in the high-teens percentage range and an EBITDA margin of 13–15%. » More on de.investing.com
SKAN increases order intake and net sales significantly and confirms full-year guidance
SKAN reports double-digit growth in the first half of 2026: order intake +16.3% to CHF 247.6m, order backlog +27.8% to CHF 442.3m and net sales +22.2% to CHF 164.5m. EBITDA rose to CHF 15.3m and the half-year profit amounted to CHF 5.4m. SKAN confirms its 2026 guidance, forecasting net sales growth in the high single-digit/upper ten-percent range and an EBITDA margin of 13–15%, and sees further growth opportunities thanks to a strong market position. » More on de.investing.com
SKAN Group records decline in sales and earnings in 2025
The Basel-based SKAN Group posted lower revenue and earnings in the 2025 fiscal year, as expected. The figures are therefore below the previous year’s level. » More on finanzen.net
SKAN: declining revenues and earnings in fiscal year 2025
The Basel-based SKAN Group reports preliminary, unaudited figures for fiscal year 2025 showing falling revenue and reduced earnings. The company provides more details in the full AWP release. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 178.19M | - |
| Gross profit | 126.32M | - |
| Net profit | 5.21M | - |
| EBITDA | 19.37M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.69B |
Number of shares | 22.48M |
52-week high/low | €83.78 - €38.70 |
Dividend yield | 0.32% |
Dividends TTM | €0.24 |
Beta | 0.79 |
P/E ratio | 52.11 |
PEG ratio | 0.62 |
P/B ratio | 13.70 |
P/S ratio | 4.29 |
Company profile
SKAN Group AG provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Asia, Europe, the Americas, and internationally. It operates in two segments: Equipment and Solutions (E&S) and Services and Consumables (S&C). The E&S segment offers mission-critical solutions for the pharmaceutical production, including isolators, integrated automated systems, and aseptic filling systems and solutions, as well as laboratory and cleanroom equipment. The S&C segment provides life cycle support and ready-to-use consumables, as well as customer- specific and digital solutions. The company was formerly known as BV Holding AG and changed its name to SKAN Group AG in October 2021. SKAN Group AG was founded in 1968 and is headquartered in Allschwil, Switzerland.
| Name | SKAN Group N |
| CEO | Jonas Greutert |
| Headquarters | Allschwil,
bl Switzerland |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 12/28/2021 |
| Employees | 1,694 |
Ticker symbols
| Exchange | Symbol |
|---|---|
SIX | SKAN.SW |
London | 0SKN.L |